Andrea Rubbert-Roth

Prof Dr

Kantonsspital St. Gallen

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Prof Dr. Andrea Rubbert-Roth is a faculty member at Kantonsspital St Gallen, Switzerland. Her research primarily focuses on the safety and efficacy of JAK inhibitors in the treatment of various autoimmune conditions, including rheumatoid arthritis and giant-cell arteritis. She has published extensively on topics such as treatment responses in immune-mediated inflammatory diseases and the implications of pharmacological interventions in diverse patient populations.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Catherine Elizabeth Raptis

Deputy Head of Science

SWITZERLAND

View details

Daniel Manoil

Karolinska Institutet

SWEDEN

View details

Raphael Micheroli

University Hospital of Zurich

SWITZERLAND

View details

Bernard Combe

Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments

University of Montpellier

FRANCE

View details

Diana Dan

Lausanne University Hospital

SWITZERLAND

View details

Roy Fleischmann

Clinical Professor of Medicine

University of Texas Southwestern Medical Center

UNITED STATES

View details

Axel Finckh

University Hospital of Geneva

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrea Rubbert-Roth

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis

Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy

Anti-interleukin-23-directed therapy and the recurrence of severe allergic asthma

Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib

Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis

Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Collaborators (7)

Catherine Elizabeth Raptis

Daniel Manoil

Raphael Micheroli

Bernard Combe

Diana Dan

Roy Fleischmann

Axel Finckh

Make your next move.